• 专利附录
  • 专利说明
  • 权利要求
  • 类似技术
  • 同族专利
  • 引用文献
  • 法律状态
  • 优先权
    • 专利摘要:
    A therapeutic or prophylactic agent for diabetes comprising a thiazolidine derivative as a PPAR-γ agonist as an effective component, which agent shows a reduced side effect of the PPAR-γ agonist, is disclosed. The therapeutic or prophylactic agent for diabetes comprises a particular IP agonist such as beraprost sodium (BPS), and a thiazolidine derivative such as pioglitazone or a pharmaceutically acceptable salt thereof. Since the therapeutic or prophylactic agent of the present invention shows a sufficiently effective hypoglycemic action without being accompanied by side effects characteristic to PPAR-γ agonists (e.g., body weight gain), the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes.
    公开号:EP2500020A1
    申请号:EP10830012
    申请日:2010-11-12
    公开日:2012-09-19
    发明作者:Takehiro Takahashi；Hiroki Kumagai；Takashi Kadowaki；Naoto Kubota；Tetsuya Kubota
    申请人:University of Tokyo NUC；Toray Industries Inc；
    IPC主号:A61K31-00
    专利说明:
    [0001] The present invention relates to a therapeutic or prophylactic agent for diabetes, with a reduced side effect. BACKGROUND ART
    [0002] Diabetes is a group of diseases whose main symptom is chronic hyperglycemia accompanied by insufficiency of the action of insulin, and involves various characteristic metabolic disorders. The number of patients suffering from diabetes shows a worldwide tendency to increase, and, due to changes in the lifestyle such as consumption of high-fat diets and lack of exercise, patients suffering from type 2 diabetes, which is a diseased state associated with risk factors such as obesity, hypertriglyceridemia, low HDL cholesteremia, glucose metabolism disorder and/or hypertension and occurs with the metabolic syndrome, are especially increasing. Since it is known that insulin resistance (insufficiency of the action of insulin) is strongly involved in the increase in the number of patients, development of a therapeutic agent for type 2 diabetes having an action to improve insulin resistance has been especially strongly demanded.
    [0003] Peroxisome proliferator-activated receptor gamma (PPAR-γ) agonists, which are nuclear receptors, are recently developed therapeutic agents for type 2 diabetes, and known to improve insulin resistance and thereby exert a hypoglycemic action, which is effective for prophylaxis and therapy of diabetes.
    [0004] As PPAR-γ agonists, only pioglitazone hydrochloride and rosiglitazone maleate are currently commercially available, but agents such as Isaglitazone, Rivoglitazone, Bardoxolone, Aleglitazar, Lobeglitazone, ZYH-1, AVE-0897, Chiglitazar, THR-0921, GFT-505, Indeglitazar, GSK-376501 and Inoglitazone are now being developed and drawing attention as agents effective for therapy of type 2 diabetes.
    [0005] On the other hand, since PPAR-γ agonists are likely to cause characteristic side effects such as edema and body weight gain, their use is restrictive. For example, PPAR-γ agonists cannot be used for patients suffering from heart failure and patients with a history of heart failure, and the body weight needs to be appropriately controlled. Since obesity is one of the risk factors for diabetes, body weight gain is a side effect which diabetics want to avoid, so that reduction of the side effects of PPAR-γ agonists has been strongly demanded.
    [0006] In view of this, a method has been disclosed in which a highly safe and effective therapeutic effect for diabetes is exerted by using a PPAR-γ agonist in combination with another therapeutic agent or prophylactic agent for diabetes having a different action mechanism (e.g., α-glycosidase inhibitor, sulfonylurea agent, biguanide, aldose reductase inhibitor, statin compound, squalene synthesis inhibitor, fibrate compound, LDL catabolism promoter or angiotensin converting enzyme inhibitor) (Patent Document 1).
    [0007] It has been disclosed that an IP agonist such as a prostaglandin I2 derivative has the actions of vasodilation, platelet aggregation inhibition, smooth-muscle proliferation inhibition, vascular endothelium protection and inflammatory cytokine inhibition and is effective as a therapeutic agent for diabetes in cases where it is used alone (Patent Document 2, Non-patent Document 1), and that an IP agonist is effective for therapy or prophylaxis of diabetes when combined with a PPAR-γ agonist (Patent Document 3). However, in Patent Document 3, the PPAR-γ agonist is merely listed as one of many arbitrary components and there is no particular description at all suggesting or supporting a combined effect with an IP agonist. Further, the fact that cicletanine, which is known as an endogenous prostacyclin inducer, exerts a synergistic therapeutic effect for diabetes when used in combination with a PPAR-γ agonist (Patent Document 4), and expected matters on lipid metabolism, control of edema and reduction of hepatotoxicity of PPAR-γ agonists are described (Patent Document 5). However, these reports do not describe that an IP agonist suppresses body weight gain due to a PPAR-γ agonist.
    [0008] An IP agonist beraprost sodium has been widely employed as an orally-available stable prostaglandin I2 derivative for basic research and clinical applications, to be used as a therapeutic agent for chronic artery obstruction (Non-patent Document 2) or primary pulmonary hypertension (Non-patent Documents 3 and 4). Since beraprost sodium and its derivatives have a platelet aggregation inhibition action, those are suggested to have possibilities to be useful as antithrombotic agents, and also reported to have an anti-hyperlipemic action (Patent Documents 6 and 7). Further, it has been discovered that beraprost sodium is effective for diabetic complications such as arterial sclerosis, diabetic nephropathy, diabetic microangiopathy, diabetic neuropathy, diabetic retinopathy and diabetic macroangiopathy (Patent Document 8), and that the combination of beraprost sodium and an antidiabetic drug enables amelioration of decrease in the functions of the motor nerve and the sensory nerve, which have not been able to be sufficiently treated with conventional antidiabetic drugs, by improvement of the nerve conduction velocity. In view of this, a therapeutic method for diabetic neuropathy using the combination of these drugs is disclosed (Patent Document 9). However, the target diseases are different in these reports, and the reports do not describe a therapeutic effect for diabetes by the combination of beraprost sodium and an antidiabetic drug. Further, it is disclosed that beraprost sodium is effective for therapy or prophylaxis of diabetes when it is used in combination with pioglitazone hydrochloride (Patent Document 3), but beraprost sodium and pioglitazone hydrochloride are merely listed as one of many combinations of IP agonist drugs and PPAR-γ agonist drugs, and there is no particular description at all suggesting or supporting the combined effect.
    [0009] However, it has not been known so far that IP agonists can be therapeutic agents or prophylactic agents which not only suppress the side effect of PPAR-γ agonists, that is, the body weight-increasing action, but also have an excellent hypoglycemic action PRIOR ART DOCUMENTS[Patent Documents]
    [0010] [Patent Document 1] JP 2007-191494 A [Patent Document 2] JP 2-167227 A [Patent Document 3] JP 2006-199694 A [Patent Document 4] Japanese Translated PCT Patent Application Laid-open No. 2006-523668 [Patent Document 5] W02006/034510 [Patent Document 6] JP 1-53672 B [Patent Document 7] JP 62-286924 A [Patent Document 8] WO99/13880 [Patent Document 9] JP 10-251146 A [Non-patent Documents]
    [0011] [Non-patent Document 1] Paolisso et al., Diabetes Care, 18, 200-205, 1995 [Non-patent Document 2] Melian et al., Drugs, 62, 107-133, 2002 [Non-patent Document 3] Hashida et al., Angiology, 49, 161-164, 1998 [Non-patent Document 4] Miyata et al., J. Cardiovasc. Pharmacol., 27, 20-26, 1996 DISCLOSURE OF THE INVENTIONPROBLEMS TO BE SOLVED BY THE INVENTION
    [0012] The present invention aims to provide a therapeutic or prophylactic agent for diabetes comprising as an effective component a PPAR-γ agonist, which agent shows a reduced side effect of the PPAR-γ agonist. MEANS FOR SOLVING THE PROBLEMS
    [0013] As a result of intensive study to solve the above-described problems, the present inventors discovered that, by employing an IP agonist at a dose at which no effective hypoglycemic action is exerted in combination with a PPAR-γ agonist at a dose at which no effective hypoglycemic action is exerted but characteristic side effects, especially an action to increase the body weight, occur, a sufficiently effective hypoglycemic action and glucose tolerance-improving action, which are not exerted by single-agent administration of each of these agents, are exerted and the side effects of the PPAR-γ agonist can be reduced, thereby completing the present invention.
    [0014] That is, the present invention is as follows. (1) A therapeutic or prophylactic agent for diabetes, comprising a combination of an IP agonist and a PPAR-γ agonist. (2) The therapeutic or prophylactic agent according to (1), wherein the IP agonist is a prostaglandin I2 derivative represented by General Formula (I):
    [0015]
    [0016] (wherein R1 represents a pharmaceutically acceptable cation or hydrogen; R2 represents hydrogen or C2-C10 acyl; R3 represents hydrogen or C2-C10 acyl; R4 represents hydrogen, methyl or ethyl; R5 represents C1-C5 linear alkyl; A represents i) —CH2—CH2—; or ii) trans —CH=CH—; and X represents trans —CH=CH—).
    [0017] (3) The therapeutic or prophylactic agent according to (2), wherein the prostaglandin I2 derivative represented by General Formula (I) is beraprost sodium.
    [0018] (4) The therapeutic or prophylactic agent according to any of (1) to (3), wherein the PPAR-γ agonist is a thiazolidine derivative.
    [0019] (5) The therapeutic or prophylactic agent according to (4), wherein the thiazolidine derivative is pioglitazone or a pharmaceutically acceptable salt thereof.
    [0020] (6) The therapeutic or prophylactic agent according to any of (1) to (5), wherein each of the IP agonist and PPAR-γ agonist is used at a dose at which a therapeutic or prophylactic effect for diabetes is not exerted by single-agent administration thereof.
    [0021] Further, the following parts in the above description are preferred in the present invention. (1)' A therapeutic or prophylactic agent for diabetes, comprising a combination of a prostaglandin I2 derivative represented by General Formula (I):
    [0022]
    [0023] (whereinR1 represents a pharmaceutically acceptable cation or hydrogen;R2 represents hydrogen or C2-C10 acyl;R3 represents hydrogen or C2-C10 acyl;R4 represents hydrogen, methyl or ethyl;R5 represents C1-C5 linear alkyl;A represents i) —CH2—CH2—; or ii) trans —CH=CH—; and X represents trans —CH=CH—)and a thiazolidine derivative.
    [0024] (2)' The therapeutic or prophylactic agent according to (1)', wherein, in the General Formula (I), both R2 and R3 are hydrogen, both R4 and R5 are methyl, and A is —CH2—CH2—.
    [0025] (3)' The therapeutic or prophylactic agent according to (2)', wherein the prostaglandin I2 derivative represented by General Formula (I) is beraprost sodium.
    [0026] (4)' The therapeutic or prophylactic agent according to any of (1)' to (3)', wherein the thiazolidine derivative is pioglitazone or a pharmaceutically acceptable salt thereof. EFFECT OF THE INVENTION
    [0027] Since the therapeutic or prophylactic agent of the present invention shows a sufficiently effective hypoglycemic action and glucose tolerance-improving action without causing side effects characteristic to PPAR-γ agonists (e.g., body weight gain), the agent is useful as a highly safe and effective therapeutic or prophylactic agent for diabetes. BEST MODE FOR CARRYING OUT THE INVENTION
    [0028] In the present invention, "IP agonist" is a general term for agents which bind to prostaglandin I2 (IP) receptors on the cell membrane to exert actions such as vasodilation, platelet aggregation inhibition, smooth-muscle proliferation inhibition, vascular endothelium protection and inflammatory cytokine inhibition. The IP agonist is preferably a prostaglandin I2 derivative represented by the General Formula (I), and the IP agonist is especially preferably beraprost, which is a compound described in JP 1-53672 B , or beraprost sodium, which is the sodium salt thereof; or Compound 1:
    [0029]
    [0030] Compound 2:
    [0031]
    [0032] The prostaglandin I2 derivatives represented by the General Formula (I) include d-isomers, 1-isomers and dl-isomers, and also include mixtures of compounds represented by the General Formula (I).
    [0033] Preferred examples of the IP agonist also include octimibate ( DE 3504677 B ) and the compounds described in this specification; ataprost ( JP 54-130543 A ) and the compounds described in this publication; CS-570 ( JP 54-95552 A ) and the compounds described in this publication; cicaprost ( JP 59-157050 A ) and the compounds described in this publication; OP-2507 ( JP 61-30519 A ) and the compounds described in this publication; clinprost ( JP 59-137445 A ) and the compounds described in this publication; pimilprost ( JP 59-141536 A ) and the compounds described in this publication; TY-11223 ( JP 03-246252 A ) and the compounds described in this publication; samixogrel ( JP 03-005457 A ) and the compounds described in this publication; epoprostenol sodium ( JP 52-136161 A ) and the compounds described in this publication; treprostinil sodium ( US 4306075 B ) and the compounds described in this specification; iloprost ( JP 55-057559 A ) and the compounds described in this publication; ibudilast( JP 48-097898 A ) and the compounds described in this publication; ozagrel sodium ( JP 55-000313 A ) and the compounds described in this publication; isbogrel ( JP 58-219162 A ) and the compounds described in this publication; TRA-418 ( WO 00/07992 ) and the compounds described in this literature; phthalazinol ( JP 50-70380 A ) and the compounds described in this publication; and NS-304 ( WO 02/088084 ) and the compounds described in this literature. Either a single type or a combination of 2 or more types of IP agonist(s) may be used.
    [0034] In the prostaglandin I2 derivatives represented by the General Formula (I), examples of the "pharmaceutically acceptable cation" include metal cations and amine cations.
    [0035] The metal cations are those induced from alkaline metals (e.g., lithium, sodium and potassium) and alkaline earth metals (e.g., magnesium and calcium). Cations induced from other metals such as aluminum, zinc and iron are of course included in the present invention.
    [0036] The amine cations are those induced from primary amines, secondary amines and tertiary amines. Examples of suitable amines include: (1) aliphatic, alicyclic and aromatic amines and heterocyclic amines, such as methylamine, dimethylamine, triethylamine, ethylamine, dibutylamine, triisopropylamine, N-methylhexylamine, decylamine, dodecylamine, allylamine, crotylamine, cyclopentylamine, dicyclohexylamine, benzylamine, dibenzylamine, α-phenylethylamine, β-phenylethylamine, ethylenediamine, diethylenetriamine, 1-methylpiperidine, 4-ethylmorpholine, 1-isopropylpyrrolidine, 2-methylpyrrolidine, 1,4-dimethylpiperazine and 2-methylpiperidine; (2) water-soluble amines and amines having a hydrophilic group(s), such as mono-ethanolamine, di-ethanolamine, triethanolamine, ethyldiethanolamine, N-butylethanolamine, 2-amino-1-butanol, 2-amino-2-ethyl-1,3-propanediol, tris(hydroxymethyl)aminomethane and N-phenylethanolamine; and (3) basic amino acids, such as lysine and arginine.
    [0037] The "C1-C5 linear alkyl" is methyl, ethyl, propyl, butyl or pentyl. Examples of the "C2-C12 acyl" include acetyl, propionyl, pentanoyl, hexanoyl and decanoyl.
    [0038] In the present invention, prostaglandin I2 derivatives represented by the General Formula (I), especially beraprost sodium, are preferred among IP agonists. Since beraprost sodium is physicochemically stable for a long period and has high oral bioavailability, effective therapy of diabetes can be realized by use of beraprost sodium in combination. Further, since beraprost sodium has been used in many clinical cases, its long-term safety in cases of administration to human has been established, so that beraprost sodium is especially preferably used.
    [0039] Beraprost sodium is already commercially available and its production method is well known. Beraprost sodium can be produced by, for example, the method described in JP 1-53672 B . Further, in the present invention, a commercially available beraprost sodium may also be preferably used. Beraprost sodium is normally used together with a pharmaceutically acceptable carrier or vehicle, in the form of a common oral pharmaceutical formulation such as a tablet, capsule, powder, granules or liquid, but the dosage form is not restricted thereto.
    [0040] Prostaglandin I2 derivatives represented by General Formula (I) other than beraprost sodium can also be produced by, for example, the method described in JP 1-53672 B .
    [0041] Compounds 1 and 2 can be produced by, for example, the method described in a known literature (Heterocycles, Vol.53, No.5, p. 1085-1110, 2000) or a salification method which is commonly used. These are normally used together with a pharmaceutically acceptable carrier or vehicle, in the form of a common oral pharmaceutical formulation such as a tablet, capsule, powder, granules or liquid, but the form is not restricted thereto.
    [0042] In the present invention, "PPAR-γ agonist" is a general term for agents which act on a nuclear receptor, peroxisome proliferator-activated receptor gamma (PPAR-γ), to enhance the insulin sensitivity. Preferred examples of the PPAR-γ agonist include pioglitazone hydrochloride and rosiglitazone maleate, which are currently commercially available; and Isaglitazone, Rivoglitazone, Bardoxolone, Aleglitazar, Lobeglitazone, ZYH-1, AVE-0897, Chiglitazar, THR-0921, GFT-505, Indeglitazar, GSK-376501 and Inoglitazone, which are currently being developed. Among PPAR-γ agonists, thiazolidine derivatives are preferred. "Thiazolidine derivatives" herein means a group of compounds having thiazolidinedione as a partial structure. Among thiazolidine derivatives, pioglitazone, which is a compound described in US 4,687,777 B and commercially available, and pharmaceutically acceptable salts thereof are especially preferred. Examples of the pharmaceutically acceptable salts include inorganic salts such as hydrochloric acid salt, nitric acid salt, hydrobromic acid salt, sulfuric acid salt, boric acid salt and phosphoric acid salt; organic acid salts such as acetic acid salt, maleic acid salt, fumaric acid salt, tartaric acid salt, succinic acid salt, malic acid salt, lactic acid salt, citric acid salt, malonic acid salt, benzoic acid salt, paratoluenesulfonic acid salt and methanesulfonic acid salt; and acid addition salts including those to which an amino acid such as lysine, glycine, phenylalanine, asparagine or glutamic acid is added. Either a single type or a combination of 2 or more types of PPAR-γ agonist(s) may be used.
    [0043] Pioglitazone hydrochloride is an excellent insulin sensitizer, and, by recovering the function of damaged insulin receptors, it normalizes the intracellular localization of glucose transporters and normalizes enzyme systems playing central roles in glucose metabolism, such as glucokinase, or lipid metabolism-related enzyme systems, such as lipoprotein lipase. This results in not only improvement of insulin resistance and glucose tolerance, but also reduction of neutral fat and free fatty acids. In addition, since pioglitazone hydrochloride has been used in many clinical cases, its long-term effectivity in human has been established, so that pioglitazone hydrochloride is especially preferably used.
    [0044] The production methods of pioglitazone and its pharmaceutically acceptable salts are well known, and the production can be carried out by, for example, the methods described in JP 55-22636 A and JP 61-267580 A . Commercially available products may also be preferably used. Pioglitazone or its pharmaceutically acceptable salt is normally used together with a pharmaceutically acceptable carrier or vehicle, in the form of a common oral pharmaceutical formulation such as a tablet, capsule, powder, granules or liquid, but the form is not restricted thereto.
    [0045] In the present invention, the combination of a compound represented by the General Formula (I), especially beraprost sodium, among IP agonists, and especially pioglitazone hydrochloride among PPAR-γ agonists is most preferred.
    [0046] In the present invention, "therapeutic or prophylactic agent for diabetes" also includes an agent which is a therapeutic agent as well as a prophylactic agent for diabetes.
    [0047] The dose of the therapeutic or prophylactic agent of the present invention may be determined according to the doses of the individual agents, and may be appropriately selected depending on the age, body weight and symptoms of the subject to whom the agent is to be administered; administration time; dosage form; administration method; combination of agents; and the like.
    [0048] In cases where the IP agonist in the present invention is used for human, it is preferred to administer the IP agonist in an amount of, for example, 1 to 1000 µg/adult/administration, preferably 5 to 500 µg/adult/administration in terms of the amount of a prostaglandin I2 derivative represented by the General Formula (I) as an effective component, which is preferably administered at one time or dividedly in about 2 to 4 times for not less than 1day, especially not less than 3 days. In cases where the IP agonist is applied to a non-human mammal, the dose is preferably 0.1 µg/kg to 100 mg/kg, more preferably 1 µg/kg to 50 mg/kg in terms of the amount of a prostaglandin I2 derivative represented by the General Formula (I) as an effective component, which is administered at one time or dividedly in about 2 to 4 times for not less than 1day, especially not less than 3 days.
    [0049] The dose of the PPAR-γ agonist in the present invention may be selected, in the cases of oral administration, within the range of 0.01 1 to 10 mg/kg body weight, which is the clinical dose (preferably 0.05 to 10 mg/kg body weight, more preferably 0.05 to 5 mg/kg body weight), and, in the cases of parenteral administration, within the range of 0.005 to 10 mg/kg body weight (preferably 0.01 to 10 mg/kg body weight, more preferably 0.01 to 1 mg/kg body weight). The administration is usually carried out 1 to 3 times a day.
    [0050] Surprisingly, as concretely described in the Examples below, an excellent therapeutic or prophylactic effect for diabetes is exerted by combined use of the IP agonist and the PPAR-γ agonist even in cases where the dose of each of these agonists is one at which a therapeutic or prophylactic effect for diabetes is not exerted by single-agent administration. In addition, although the PPAR-γ agonist causes side effects such as body weight gain even at such a dose, the IP agonist reduces the side effects of the PPAR-γ agonist. Therefore, in the present invention, by using the IP agonist and the PPAR-γ agonist such that each of these is administered at a dose at which a therapeutic or prophylactic effect for diabetes is not exerted by single-agent administration and at which the IP agonist reduces side effects of the PPAR-γ agonist, an excellent therapeutic or prophylactic effect can be achieved while reduction of the side effects and reduction of the cost of therapy can be achieved (reduction of the dose of the agent, of course, results in a lower cost), which is preferred. Such a dose of the IP agonist is, in the cases of oral administration, 5 to 500 µg/adult/administration, preferably 5 to 250 µg/adult/administration, which is preferably administered at one time or dividedly in about 2 to 4 times for not less than 1day, especially not less than 3 days. The dose of the PPAR-γ agonist may be selected, in the cases of oral administration, within the range of 0.05 to 1.0 mg/kg body weight, preferably 0.05 to 0.5 mg/kg body weight, and, in the cases of parenteral administration, within the range of 0.025 to 1.0 mg/kg body weight, preferably 0.025 to 0.5 mg/kg body weight. The administration is usually carried out 1 to 3 times a day.
    [0051] The administration method is not restricted and may be selected from, for example, oral administration, subcutaneous administration, intravenous or intravascular administration, intramuscular administration, pulmonary administration, intraduodenal administration and intraperitoneal administration. A more preferred dosage form is oral administration.
    [0052] In the present invention, the IP agonist, for example, a prostaglandin I2 derivative represented by the General Formula (I), may be formulated as appropriate using a pharmaceutically acceptable additive which is necessary for the formulation. More particularly, examples of a vehicle which may be contained in the formulation include sugars such as lactose, mannitol, xylitol and dextrin; starches such as corn starch, hydroxypropyl starch and partially-alphanized starch; cellulose derivatives such as crystalline cellulose, hydroxypropyl cellulose, hydroxypropyl methylcellulose and sodium carboxymethylcellulose; polyvinylpyrrolidone; polyethylene oxide 5000K; and mixtures composed of 2 or more of these. Examples of a binder which may be contained in the formulation include hydroxypropyl cellulose (HPC), hydroxypropyl methylcellulose (HPMC), methyl cellulose (MC), sodium carboxymethylcellulose (CMCNa), polyvinylpyrrolidone (PVP), polyethylene glycol (PEG), starch, Macrogol 6000, L-glutamic acid, magnesium stearate, and mixtures composed of 2 or more of these.
    [0053] In the present invention, the IP agonist, such as a formulation containing a prostaglandin I2 derivative represented by the General Formula (I), may be administered either orally or parenterally.
    [0054] In the cases of oral administration, the prostaglandin I2 derivative represented by the General Formula (I) may be formulated into a tablet, powder, fine granules, granules, tablet, liquid, syrup, capsule, pill or spray. In such cases, the shaped product may be coated with a film, coated with sugar or filled in a capsule. Formulation into a tablet, fine granules, granules, powder or liquid is especially preferred. Alternatively, when a prostaglandin I2 derivative represented by the General Formula (I) is formulated, the effective component may be included in a food to prepare a formula meal. Such a formula meal may be in the form of a solid, semifluid or solution.
    [0055] In the cases of parenteral administration, the IP agonist, such as a prostaglandin I2 derivative represented by the General Formula (I), may be formulated into various injection solutions or suppository. In such cases, another solute such as sodium chloride or glucose enough to make the solution isotonic may be used, or the formulation may be prepared into a sustained-release formulation by a known method such as use of a hydrogel.
    [0056] The administration route of the PPAR-γ agonist used in the present invention is commonly oral administration. The unit dosage form is not restricted as long as it is prepared by a normal formulation technique, and examples thereof include powders, granules, tablets and capsules.
    [0057] These various formulations may be prepared according to conventional methods using known auxiliary materials which may be normally used in the field of formulation of pharmaceuticals, such as vehicles, binders, disintegrators, lubricants, solubilizers, correctives and coating agents.
    [0058] For example, as a carrier used for shaping into a tablet, those known in the art may be widely used, and specific examples of the carrier include vehicles such as lactose, saccharose, sodium chloride, glucose, urea, starch, calcium carbonate, kaolin, crystalline cellulose and silicic acid; binders such as water, ethanol, propanol, simple syrup, glucose solutions, starch solutions, gelatin solutions, carboxymethyl cellulose, shellac, methyl cellulose, potassium phosphate and polyvinyl pyrrolidone; disintegrators such as dry starch, sodium alginate, agar powder, laminaran powder, sodium hydrogen carbonate, calcium carbonate, polyoxyethylene sorbitan fatty acid esters, sodium lauryl sulfate, stearic acid monoglyceride, starch and lactose; disintegration suppressing agents such as saccharose, stearin, cacao butter and hydrogenated oil; absorption enhancers such as quaternary ammonium base and sodium lauryl sulfate; moisturizers such as glycerin and starch; adsorbents such as starch, lactose, kaolin, bentonite and colloidal silicic acid; and lubricants such as purified talc, stearate, boric acid powder and polyethylene glycol. The tablet may be prepared as a tablet with a normal coating, such as a sugar-coated tablet, gelatin-coated tablet, enteric-coated tablet or film-coated tablet, or a bilayer tablet or multilayer tablet.
    [0059] As a carrier used for shaping into a pill, those known in the art may be widely used, and specific examples of the carrier include vehicles such as glucose, lactose, starch, cacao butter, hydrogenated vegetable oil, kaolin and talc; binders such as gum arabic powder, powdered tragacanth, gelatin and ethanol; and disintegrators such as laminaran agar. Further, as required, a coloring agent, preservative, perfume, flavoring agent, sweetener and/or another drug may be contained..
    [0060] The amount of the PPAR-γ agonist contained in the pharmaceutical formulation is not restricted and may be appropriately selected from a wide range, and the amount is usually 1 to 70% by weight, preferably 1 to 30% by weight with respect to the total amount of the composition.
    [0061] The therapeutic or prophylactic agent of the present invention may be administered in the form of a combination drug. Alternatively, a plurality of individual agents may be administered at the same time. Alternatively, the individual agents may be administered at appropriate intervals. The intervals acceptable for allowing an effect caused by administration of the drug to be achieved can be confirmed clinically or by an animal experiment. Each single agent is formulated into a form appropriate for the compound, and then administered. The administration route may be different among the agents.
    [0062] In the therapeutic or prophylactic agent of the present invention, in cases where a side effect, especially body weight gain, was observed as a result of administration of a PPAR-γ agonist, the dose of the PPAR-γ agonist may be reduced as appropriate to within the range whose upper limit is a dose at which a clinically acceptable minor side effect occurs.
    [0063] Further, in the present invention, a known antidiabetic agent may be used in combination. Examples of the known antidiabetic agent include PPAR-α agonists, PPAR- δ agonists, retinoid RXR agonists, β3-adrenaline receptor agonists, 11β-hydroxysteroid dehydrogenase inhibitors, protein tyrosine phosphatase-1B (PTP-1B) inhibitors, AMP-activated protein kinase (AMPK) activators, acetyl-CoA carboxylase (ACC) inhibitors, cannabinoid receptor 1(CB1) antagonists, insulin secretagogues (ATP-dependent potassium channel inhibitors (sulfonylurea drugs, sulfonamide drugs, phenylalanine derivatives and the like)), biguanides, α-glucosidase inhibitors, insulin formulations, insulin analogues, dipeptidyl peptidase IV inhibitors, glucagon-like peptide 1 (GLP1) agonists and GLP1. These known antidiabetic agents may also be administered in the form of a combination drug. Alternatively, a plurality of individual agents may be administered at the same time. Alternatively, the individual agents may be administered at appropriate intervals.
    [0064] Examples of the method of evaluation of the therapeutic or prophylactic effect for diabetes in the present invention include blood glucose measurement, the glucose tolerance test and the hyperinsulinemic euglycemic glucose clamp method, and, in particular, blood glucose measurement and the glucose tolerance test are employed as diagnostic methods for diabetes.
    [0065] The present invention will now be described more concretely by way of Examples below, but the present invention is not restricted to these Examples. EXAMPLESExample 1Combined Effect of Beraprost Sodium (BPS) and Pioglitazone Hydrochloride on Blood Glucose Level and Body Weight of KKAy Mice
    [0066] For the experiment, male KKAy mice (CLEA Japan, Inc.) were used. KKAy mice show obesity and high blood glucose from 7 or 8 weeks old, and are commonly used as model mice for type 2 diabetes. The KKAy mice were purchased when they were 5 weeks old, and, from immediately thereafter, fed with CMF feed (Oriental Yeast Co., Ltd.) for 3 weeks under free food/water intake conditions, before being subjected to the experiment. For continuous subcutaneous administration of a solvent (physiological saline, 6 µL/day) or BPS (1 mg/kg/day, commercially available product from Toray Industries, Inc.), a minipump for sustained release (Alzet micro osmotic pump model 1002, Alzet osmotic pumps company) was subcutaneously placed in each KKAy mouse. The continuous administration of physiological saline or BPS was carried out until the end of the experiment. From 3 days after the placement (beginning of the subcutaneous continuous administration), oral administration of a solvent (0.5% methyl cellulose (MC) solution, 10 mL/kg) or pioglitazone hydrochloride (product synthesized in Toray Industries, Inc.) was started. Pioglitazone hydrochloride was administered as a suspension in 0.5% MC solution. The 0.5% MC solution and pioglitazone hydrochloride were administered for 10 days, during which the administration was carried out once per day in the evening. The mice were divided into the following experimental groups.
    [0067] (1) Control group (n=8): physiological saline (6 µL/day) + 0.5% MC solution (10 mL/kg)(2) BPS group (n=6): BPS (1 mg/kg/day) + 0.5% MC solution (10 mL/kg)(3) Pioglitazone hydrochloride 3 mg group (n=6): physiological saline (6 µL/day) + pioglitazone hydrochloride (3 mg/kg)(4) BPS/pioglitazone hydrochloride 3 mg-combined-use group (n=6): BPS (1 mg/kg/day) + pioglitazone hydrochloride (3 mg/kg)(5) Pioglitazone hydrochloride 30 mg group (n=6): physiological saline (6 µL/day) + pioglitazone hydrochloride (30 mg/kg)
    [0068] The body weight and the casual blood glucose level were measured on the day before starting of the continuous administration of physiological saline or BPS (these correspond to the data shown in the "Before administration" columns in Tables 1 and 2). The body weight was measured when 0.5% MC solution or pioglitazone hydrochloride was finally administered, and the casual blood glucose level was measured about 18 hours after the final administration (these correspond to the data shown in the "After administration" columns in Tables 1 and 2). The casual blood glucose level was measured by collecting about 5 µL of blood from the tail vein and subjecting the blood to measurement with a simplified blood glucose meter (Medisense Precision Xceed, ABBOTT JAPAN Co., LTD.).
    [0069] As a result, as shown in Table 1, the BPS group and the pioglitazone hydrochloride 3 mg group showed no change in the casual blood glucose level compared to the value observed before the beginning of drug administration. On the other hand, the BPS/pioglitazone hydrochloride 3 mg-combined-use group and the pioglitazone hydrochloride 30 mg group showed significant decrease in the casual blood glucose level compared to the value observed before the beginning of drug administration, and the extent of the action was similar between these groups.
    [0070] In terms of the action on the body weight, as shown in Table 2, the pioglitazone hydrochloride 3 mg group and the pioglitazone hydrochloride 30 mg group showed significant increase in the body weight compared to the value observed before the beginning of drug administration. On the other hand, the BPS/pioglitazone hydrochloride 3 mg-combined-use group showed no change in the body weight compared to the value observed before the beginning of drug administration.
    [0071] Thus, it was revealed that, by combined administration of BPS at a dose at which a sufficiently effective hypoglycemic action is not exerted by single-agent administration and 3 mg of pioglitazone hydrochloride, an action to decrease the casual blood glucose level is exerted to almost the same extent as in the case of administration of 30 mg/kg pioglitazone hydrochloride, and the body weight-increasing action, which is observed after single-agent administration of 3 mg/kg pioglitazone hydrochloride, can be suppressed.
    [0072] Table 1. Casual blood glucose levels observed before and after administration of drugs (in KKAy mice) Casual blood glucose level (mg/dL±standard error) Experiment group Number of examples Before administration After administration Control 8 475.3 ± 25.3 426.4 ± 42.0 BPS 6 493.0 ± 35.6 392.3 ± 28.9 Pioglitazone hydrochloride 3 mg 6 450.3 ± 15.4 452.8 ± 53.4 Combined use of BPS/Pioglitazone hydrochloride 3 mg 6 471.5 ± 26.3 334.2 ± 30.8** Pioglitazone hydrochloride 30 mg 6 437.7 ± 21.7 271.3 ± 16.9** **p<0.01, paired t-test for data obtained before and after administration of each drug Each value in the table represents the mean±standard error among individuals.
    [0073] Table 2. Body weights observed before and after administration of drugs (in KKAy mice) Body weight (g±standard error) Experiment group Number of examples Before administration After administration Control 8 42.4 ± 0.8 43.4 ± 1.1 BPS 6 41.2 ± 0.8 42.3 ± 1.1 Pioglitazone hydrochloride 3 mg 6 41.7 ± 1.2 44.2 ± 1.3** Combined use of BPS/Pioglitazone hydrochloride 3 mg 6 41.9 ± 1.2 43.7 ± 1.8 Pioglitazone hydrochloride 30 mg 6 42.6 ± 1.1 46.7 ± 1.3** **p<0.01, paired t-test for data obtained before and after administration of each drug Each value in the table represents the mean±standard error among individuals. Example 2Combined Effect of Beraprost Sodium (BPS) and Pioglitazone Hydrochloride on Glucose Tolerance of KKAy Mice
    [0074] For the experiment, male KKAy mice (CLEA Japan, Inc.) were used. The KKAy mice were purchased when they were 5 or 7 weeks old, and, from immediately thereafter, fed with CMF feed (Oriental Yeast Co., Ltd.) for 2 to 4 weeks under free food/water intake conditions, before being subjected to the experiment. After dividing the mice into groups, oral administration of a solvent (0.5% methyl cellulose (MC) solution, 10 mL/kg) or pioglitazone hydrochloride (product synthesized in Toray Industries, Inc.) was started. Pioglitazone hydrochloride was administered as a suspension in 0.5% MC solution. The MC solution and pioglitazone hydrochloride were administered for 20 days, during which the administration was carried out once per day in the evening. Six days after the beginning of administration of the MC solution and pioglitazone hydrochloride, for continuous subcutaneous administration of a solvent (physiological saline, 6 µL/day) or BPS (1 mg/kg/day, commercially available product from Toray Industries, Inc.), a minipump for sustained release (Alzet micro osmotic pump model 1002, Alzet osmotic pumps company) was subcutaneously placed in each KKAy mouse. The continuous administration of physiological saline or BPS was carried out until the end of the experiment. The experimental groups were as follows.
    [0075] (1) Control group (n=6): physiological saline (6 µL/day) + 0.5% MC solution (10 mL/kg)(2) BPS group (n=5): BPS (1 mg/kg/day) + 0.5% MC solution (10 mL/kg)(3) Pioglitazone hydrochloride 3 mg group (n=5): physiological saline (6 µL/day) + pioglitazone hydrochloride (3 mg/kg)(4) BPS/pioglitazone hydrochloride 3 mg-combined-use group (n=6): BPS (1 mg/kg/day) + pioglitazone hydrochloride (3 mg/kg)(5) Pioglitazone hydrochloride 30 mg group (n=6): physiological saline (6 µL/day) + pioglitazone hydrochloride (30 mg/kg)
    [0076] After the final oral administration of 0.5% MC solution and pioglitazone hydrochloride, a glucose tolerance test was carried out. This glucose tolerance test was carried out by fasting the mice for not less than 17 hours and performing forced oral administration of an aqueous glucose solution (1.5 g/10 mL/kg) under unanesthetized conditions. The blood glucose level was measured immediately before the administration of glucose (this timing is regarded as "0 minute") and 15, 30, 60 and 120 minutes after the administration of glucose. The blood glucose level was measured by collecting about 5 µL of blood from the tail vein and subjecting the blood to measurement with a simplified blood glucose meter (Glutest Ace R, ARKRAY, Inc./Sanwa Kagaku Kenkyusho Co., Ltd.). The increase in the blood glucose level at each timing relative to the blood glucose level observed immediately before the administration of glucose (0 minute) was defined as Δblood glucose level. The length of time (minutes) after the administration of glucose was plotted along the abscissa and Δblood glucose level (mg/dL) was plotted along the ordinate, to calculate the area under the Δblood glucose level-time curve from 0 minute to 120 minutes (ΔAUC0-120).
    [0077] As a result, as shown in Table 3, the BPS group and the pioglitazone hydrochloride 3 mg group showed no change in ΔAUC0-120 compared to the control group. On the other hand, the BPS/pioglitazone hydrochloride 3 mg-combined-use group showed significant decrease in ΔAUC0-120 compared to the control group, so that a glucose tolerance-improving action was observed. The amount of decrease in the value was significantly larger than that observed in the pioglitazone hydrochloride 30 mg group.
    [0078] Thus, it was revealed that, by combined use of BPS and pioglitazone hydrochloride, each at a dose at which a hypoglycemic action is not exerted by single-agent administration, a glucose tolerance-improving action is exerted in KKAy mice to almost the same or a higher extent compared to the case of administration of 30 mg/kg pioglitazone hydrochloride, indicating that the combination shows a sufficient effect as a therapeutic and prophylactic agent for diabetes.
    [0079] Table 3. The area under the Δblood glucose level-time curve (ΔAUC0-120) in the glucose tolerance test after administration of a drug (in KKAy mice) Experiment group Number of examples ΔAUC0-120 Control 6 26266 ± 3753 BPS 5 18684 ± 3551 Pioglitazone hydrochloride 3 mg 5 23138 ± 4870 Combined use of BPS/Pioglitazone hydrochloride 3 mg 6 13159 ± 2056*#Pioglitazone hydrochloride 30 mg 6 22461 ± 2157 *p<0.05, t-test against the control group#p<0.05, t-test against the pioglitazone hydrochloride 30 mg group Each value in the table represents the mean±standard error among individuals. INDUSTRIAL APPLICABILITY
    [0080] By the present invention, it was confirmed that combined administration of an IP agonist, especially a prostaglandin I2 derivative represented by the General Formula (I), with a PPAR-γ agonist enhances the hypoglycemic action of the PPAR-γ agonist, reduces side effects (especially body weight gain), and allows a glucose tolerance-improving action. Therefore, the therapeutic or prophylactic agent of the present invention by combination of an IP agonist and a PPAR-γ agonist can be expected to be an excellent therapeutic or prophylactic agent for diabetes, in which side effects of the PPAR-γ agonist are reduced.
    权利要求:
    Claims (4)
    [0001] A therapeutic or prophylactic agent for diabetes, comprising a combination of a prostaglandin I2 derivative represented by General Formula (I):
    [0002] The therapeutic or prophylactic agent according to claim 1, wherein, in said General Formula (I), both R2 and R3 are hydrogen, both R4 and R5 are methyl, and A is —CH2—CH2—.
    [0003] The therapeutic or prophylactic agent according to claim 2, wherein said prostaglandin I2 derivative represented by General Formula (I) is beraprost sodium.
    [0004] The therapeutic or prophylactic agent according to any one of claims 1 to 3, wherein said thiazolidine derivative is pioglitazone or a pharmaceutically acceptable salt thereof.
    类似技术:
    公开号 | 公开日 | 专利标题
    US10426763B2|2019-10-01|Pharmaceutical compositions comprising glitazones and NRF2 activators
    US10251867B2|2019-04-09|Dosing regimen for a selective S1P1 receptor agonist
    JP6066144B2|2017-01-25|Concomitant medication
    JP6676108B2|2020-04-08|Lixisenatide and metformin for the treatment of type 2 diabetes
    US6258837B1|2001-07-10|Neuropeptide Y receptor antagonist
    EP3038654B1|2019-10-30|New use
    RU2667643C2|2018-09-21|Nep inhibitors for treating diseases characterized by atrial enlargement or remodeling
    EP2275108B1|2014-07-09|Pharmaceutical preparation comprising dpp-iv inhibitor and other diabetes therapeutic agent in concomitant or combined form
    Croxtall et al.2008|Vildagliptin
    KR101302838B1|2013-09-03|Roflumilast for the treatment of diabetes mellitus
    EP1461070B1|2007-01-24|Combined use of a glp-1 compound and an aldose reductase inhibitor
    US20040209891A1|2004-10-21|Treatment of type 2 diabetes with inhibitors of dipeptidyl peptidase IV
    EP3492077A1|2019-06-05|Synthetic triterpenoids and methods of use in the treatment of disease
    JP2014001234A|2014-01-09|Treatment for the complication of diabetes
    EP2135603B1|2013-01-02|Compositions and methods for increasing insulin sensitivity
    JP2007538015A|2007-12-27|How to use drugs in combination to treat insulin resistance
    AU2015320975B2|2020-10-08|Combination treatment of SGLT2 inhibitors and dopamine agonists for preventing metabolic disorders in equine animals
    EP1696932B1|2009-09-02|Use of treprostinil to improve kidney functions
    US20060189535A1|2006-08-24|Combination treatment using exendins and thiazolidinediones
    JP2021059583A|2021-04-15|Use of CXCR4 antagonists
    CA2303577C|2003-06-10|Qt dispersion and heart rate variability improvement with crf antagonists to prevent sudden death
    EP2982373B1|2018-06-13|Methods and compostions for reducing body fat
    EP1306088B1|2007-09-05|Combination of a benzimidazole having angiotensin-II antagonistic activity with a diuretic
    JP2010502670A|2010-01-28|Combination therapy for diabetes mellitus
    US8536138B2|2013-09-17|Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
    同族专利:
    公开号 | 公开日
    MX2012005500A|2012-08-03|
    TW201127387A|2011-08-16|
    ES2525748T3|2014-12-29|
    CN102655866A|2012-09-05|
    KR20120087987A|2012-08-07|
    CN102655866B|2013-11-13|
    JPWO2011059053A1|2013-04-04|
    US20120258988A1|2012-10-11|
    US9492422B2|2016-11-15|
    JP5697260B2|2015-04-08|
    EP2500020B1|2014-09-10|
    CA2780683A1|2011-05-19|
    BR112012011237A2|2019-09-24|
    TWI513462B|2015-12-21|
    EP2500020A4|2013-02-06|
    KR101701943B1|2017-02-02|
    WO2011059053A1|2011-05-19|
    引用文献:
    公开号 | 申请日 | 公开日 | 申请人 | 专利标题
    法律状态:
    2012-08-17| PUAI| Public reference made under article 153(3) epc to a published international application that has entered the european phase|Free format text: ORIGINAL CODE: 0009012 |
    2012-09-19| 17P| Request for examination filed|Effective date: 20120525 |
    2012-09-19| AK| Designated contracting states|Kind code of ref document: A1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2013-02-06| RIC1| Information provided on ipc code assigned before grant|Ipc: A61P 43/00 20060101ALI20130102BHEP Ipc: A61P3/04 20060101ALI20130102BHEP Ipc: A61K 31/343 20060101ALI20130102BHEP Ipc: A61P3/10 20060101ALI20130102BHEP Ipc: A61K 31/443920060101AFI20130102BHEP |
    2013-02-06| A4| Supplementary search report drawn up and despatched|Effective date: 20130108 |
    2013-02-20| DAX| Request for extension of the european patent (deleted)|
    2014-05-30| GRAP| Despatch of communication of intention to grant a patent|Free format text: ORIGINAL CODE: EPIDOSNIGR1 |
    2014-06-25| INTG| Intention to grant announced|Effective date: 20140530 |
    2014-08-01| GRAS| Grant fee paid|Free format text: ORIGINAL CODE: EPIDOSNIGR3 |
    2014-08-08| GRAA| (expected) grant|Free format text: ORIGINAL CODE: 0009210 |
    2014-09-10| AK| Designated contracting states|Kind code of ref document: B1 Designated state(s): AL AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HR HU IE IS IT LI LT LU LV MC MK MT NL NO PL PT RO RS SE SI SK SM TR |
    2014-09-10| REG| Reference to a national code|Ref country code: GB Ref legal event code: FG4D |
    2014-09-15| REG| Reference to a national code|Ref country code: CH Ref legal event code: EP |
    2014-10-08| REG| Reference to a national code|Ref country code: IE Ref legal event code: FG4D |
    2014-10-15| REG| Reference to a national code|Ref country code: AT Ref legal event code: REF Ref document number: 686308 Country of ref document: AT Kind code of ref document: T Effective date: 20141015 |
    2014-10-23| REG| Reference to a national code|Ref country code: DE Ref legal event code: R096 Ref document number: 602010018948 Country of ref document: DE Effective date: 20141023 |
    2014-12-29| REG| Reference to a national code|Ref country code: ES Ref legal event code: FG2A Ref document number: 2525748 Country of ref document: ES Kind code of ref document: T3 Effective date: 20141229 |
    2015-01-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: GR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141211 Ref country code: LT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: SE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: NO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141210 Ref country code: FI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2015-02-11| REG| Reference to a national code|Ref country code: NL Ref legal event code: VDEP Effective date: 20140910 |
    2015-02-25| REG| Reference to a national code|Ref country code: LT Ref legal event code: MG4D |
    2015-02-27| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: CY Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: LV Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: HR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: RS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2015-03-15| REG| Reference to a national code|Ref country code: AT Ref legal event code: MK05 Ref document number: 686308 Country of ref document: AT Kind code of ref document: T Effective date: 20140910 |
    2015-03-31| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: NL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2015-04-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: EE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: IS Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150110 Ref country code: PT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20150112 Ref country code: SK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: RO Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: CZ Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2015-05-29| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: PL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: AT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2015-06-11| REG| Reference to a national code|Ref country code: DE Ref legal event code: R097 Ref document number: 602010018948 Country of ref document: DE |
    2015-06-30| REG| Reference to a national code|Ref country code: CH Ref legal event code: PL |
    2015-06-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: BE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 Ref country code: MC Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: LU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20141112 |
    2015-07-17| PLBE| No opposition filed within time limit|Free format text: ORIGINAL CODE: 0009261 |
    2015-07-17| STAA| Information on the status of an ep patent application or granted ep patent|Free format text: STATUS: NO OPPOSITION FILED WITHIN TIME LIMIT |
    2015-07-31| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: DK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: LI Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 Ref country code: CH Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141130 |
    2015-08-19| 26N| No opposition filed|Effective date: 20150611 |
    2015-08-26| REG| Reference to a national code|Ref country code: IE Ref legal event code: MM4A |
    2015-10-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: IE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20141112 |
    2015-11-24| REG| Reference to a national code|Ref country code: FR Ref legal event code: PLFP Year of fee payment: 6 |
    2015-11-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: SI Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2016-04-29| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: SM Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2016-06-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: BG Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2016-07-29| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: BE Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: HU Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT; INVALID AB INITIO Effective date: 20101112 Ref country code: MT Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: TR Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2016-11-24| REG| Reference to a national code|Ref country code: FR Ref legal event code: PLFP Year of fee payment: 7 |
    2017-01-31| PGFP| Annual fee paid to national office [announced via postgrant information from national office to epo]|Ref country code: FR Payment date: 20161124 Year of fee payment: 7 Ref country code: GB Payment date: 20161124 Year of fee payment: 7 |
    2017-02-28| PGFP| Annual fee paid to national office [announced via postgrant information from national office to epo]|Ref country code: IT Payment date: 20161124 Year of fee payment: 7 Ref country code: ES Payment date: 20161124 Year of fee payment: 7 |
    2017-04-28| PGFP| Annual fee paid to national office [announced via postgrant information from national office to epo]|Ref country code: DE Payment date: 20161220 Year of fee payment: 7 |
    2018-06-02| REG| Reference to a national code|Ref country code: DE Ref legal event code: R119 Ref document number: 602010018948 Country of ref document: DE |
    2018-06-29| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: MK Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 |
    2018-07-25| GBPC| Gb: european patent ceased through non-payment of renewal fee|Effective date: 20171112 |
    2018-08-31| REG| Reference to a national code|Ref country code: FR Ref legal event code: ST Effective date: 20180731 |
    2018-10-31| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: AL Free format text: LAPSE BECAUSE OF FAILURE TO SUBMIT A TRANSLATION OF THE DESCRIPTION OR TO PAY THE FEE WITHIN THE PRESCRIBED TIME-LIMIT Effective date: 20140910 Ref country code: DE Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20180602 Ref country code: FR Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171130 Ref country code: IT Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171112 |
    2018-11-30| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: GB Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171112 |
    2018-12-26| REG| Reference to a national code|Ref country code: ES Ref legal event code: FD2A Effective date: 20181226 |
    2019-02-28| PG25| Lapsed in a contracting state [announced via postgrant information from national office to epo]|Ref country code: ES Free format text: LAPSE BECAUSE OF NON-PAYMENT OF DUE FEES Effective date: 20171113 |
    优先权:
    申请号 | 申请日 | 专利标题
    [返回顶部]